Dietary supplementation with cis-9, trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults

Ivonne Sluijs, Yvonne Plantinga, Baukje De Roos, Louise I. Mennen, Michiel L. Bots

    Research output: Contribution to journalArticle

    56 Citations (Scopus)

    Abstract

    Background: Animal studies suggest that dietary cis-9, trans-11 (c9,t11) conjugated linoleic acid (CLA) may inhibit or regress the development of atherosclerosis. The effect of CLA on atherosclerosis has not been assessed in humans.

    Objective: We investigated the effect of c9,t11 CLA supplementation on aortic pulse wave velocity (a marker of atherosclerosis) and on cardiovascular risk factors in overweight and obese but otherwise apparently healthy subjects.

    Design: In a double-blind, randomized, placebo-controlled, parallel-group trial, we randomly assigned 401 subjects, aged 40-70 y and with a body mass index (in kg/m(2)) > 25, to receive either 4 g CLA/d (2.5 g c9,t11 CLA/d and 0.6 g trans-10, cis-12 CLA/d) or placebo supplements for 6 mo. Aortic pulse wave velocity, blood pressure, anthropometric characteristics, and concentrations of fasting lipid, glucose, insulin, and C-reactive protein were measured before and after supplementation.

    Results: During the intervention, mean (+/- SE) pulse wave velocity did not change in the c9,t11 CLA group (Delta 0.00 +/- 0.07) compared with the placebo group (Delta 0.09 +/- 0.06). There was no effect of c9,t11 CLA supplementation on blood pressure, body composition, insulin resistance, or concentrations of lipid, glucose, and C-reactive protein.

    Conclusion: This study does not support an antiatherosclerotic effect or an effect on cardiovascular risk factors of c9,t11 CLA. This trial was registered at www.clinicaltrials.gov as NCT00706745. Am J Clin Nutr 2010; 91: 175-83.

    Original languageEnglish
    Pages (from-to)175-183
    Number of pages9
    JournalThe American Journal of Clinical Nutrition
    Volume91
    Issue number1
    Early online date18 Nov 2009
    DOIs
    Publication statusPublished - Jan 2010

    Keywords

    • pulse-wave velocity
    • modified Baecke questionnaire
    • LDL-phenotype-B
    • E knockout mice
    • fatty-acids
    • cardiovascular-disease
    • postmenopausal women
    • endothelial function
    • lipid-peroxidation
    • insulin-resistance

    Cite this

    Dietary supplementation with cis-9, trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults. / Sluijs, Ivonne; Plantinga, Yvonne; De Roos, Baukje; Mennen, Louise I.; Bots, Michiel L.

    In: The American Journal of Clinical Nutrition, Vol. 91, No. 1, 01.2010, p. 175-183.

    Research output: Contribution to journalArticle

    @article{853f6446f98c4b03b762fb04185ce260,
    title = "Dietary supplementation with cis-9, trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults",
    abstract = "Background: Animal studies suggest that dietary cis-9, trans-11 (c9,t11) conjugated linoleic acid (CLA) may inhibit or regress the development of atherosclerosis. The effect of CLA on atherosclerosis has not been assessed in humans.Objective: We investigated the effect of c9,t11 CLA supplementation on aortic pulse wave velocity (a marker of atherosclerosis) and on cardiovascular risk factors in overweight and obese but otherwise apparently healthy subjects.Design: In a double-blind, randomized, placebo-controlled, parallel-group trial, we randomly assigned 401 subjects, aged 40-70 y and with a body mass index (in kg/m(2)) > 25, to receive either 4 g CLA/d (2.5 g c9,t11 CLA/d and 0.6 g trans-10, cis-12 CLA/d) or placebo supplements for 6 mo. Aortic pulse wave velocity, blood pressure, anthropometric characteristics, and concentrations of fasting lipid, glucose, insulin, and C-reactive protein were measured before and after supplementation.Results: During the intervention, mean (+/- SE) pulse wave velocity did not change in the c9,t11 CLA group (Delta 0.00 +/- 0.07) compared with the placebo group (Delta 0.09 +/- 0.06). There was no effect of c9,t11 CLA supplementation on blood pressure, body composition, insulin resistance, or concentrations of lipid, glucose, and C-reactive protein.Conclusion: This study does not support an antiatherosclerotic effect or an effect on cardiovascular risk factors of c9,t11 CLA. This trial was registered at www.clinicaltrials.gov as NCT00706745. Am J Clin Nutr 2010; 91: 175-83.",
    keywords = "pulse-wave velocity, modified Baecke questionnaire, LDL-phenotype-B, E knockout mice, fatty-acids, cardiovascular-disease, postmenopausal women, endothelial function, lipid-peroxidation, insulin-resistance",
    author = "Ivonne Sluijs and Yvonne Plantinga and {De Roos}, Baukje and Mennen, {Louise I.} and Bots, {Michiel L.}",
    year = "2010",
    month = "1",
    doi = "10.3945/ajcn.2009.28192",
    language = "English",
    volume = "91",
    pages = "175--183",
    journal = "The American Journal of Clinical Nutrition",
    issn = "0002-9165",
    publisher = "American Society for Nutrition",
    number = "1",

    }

    TY - JOUR

    T1 - Dietary supplementation with cis-9, trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults

    AU - Sluijs, Ivonne

    AU - Plantinga, Yvonne

    AU - De Roos, Baukje

    AU - Mennen, Louise I.

    AU - Bots, Michiel L.

    PY - 2010/1

    Y1 - 2010/1

    N2 - Background: Animal studies suggest that dietary cis-9, trans-11 (c9,t11) conjugated linoleic acid (CLA) may inhibit or regress the development of atherosclerosis. The effect of CLA on atherosclerosis has not been assessed in humans.Objective: We investigated the effect of c9,t11 CLA supplementation on aortic pulse wave velocity (a marker of atherosclerosis) and on cardiovascular risk factors in overweight and obese but otherwise apparently healthy subjects.Design: In a double-blind, randomized, placebo-controlled, parallel-group trial, we randomly assigned 401 subjects, aged 40-70 y and with a body mass index (in kg/m(2)) > 25, to receive either 4 g CLA/d (2.5 g c9,t11 CLA/d and 0.6 g trans-10, cis-12 CLA/d) or placebo supplements for 6 mo. Aortic pulse wave velocity, blood pressure, anthropometric characteristics, and concentrations of fasting lipid, glucose, insulin, and C-reactive protein were measured before and after supplementation.Results: During the intervention, mean (+/- SE) pulse wave velocity did not change in the c9,t11 CLA group (Delta 0.00 +/- 0.07) compared with the placebo group (Delta 0.09 +/- 0.06). There was no effect of c9,t11 CLA supplementation on blood pressure, body composition, insulin resistance, or concentrations of lipid, glucose, and C-reactive protein.Conclusion: This study does not support an antiatherosclerotic effect or an effect on cardiovascular risk factors of c9,t11 CLA. This trial was registered at www.clinicaltrials.gov as NCT00706745. Am J Clin Nutr 2010; 91: 175-83.

    AB - Background: Animal studies suggest that dietary cis-9, trans-11 (c9,t11) conjugated linoleic acid (CLA) may inhibit or regress the development of atherosclerosis. The effect of CLA on atherosclerosis has not been assessed in humans.Objective: We investigated the effect of c9,t11 CLA supplementation on aortic pulse wave velocity (a marker of atherosclerosis) and on cardiovascular risk factors in overweight and obese but otherwise apparently healthy subjects.Design: In a double-blind, randomized, placebo-controlled, parallel-group trial, we randomly assigned 401 subjects, aged 40-70 y and with a body mass index (in kg/m(2)) > 25, to receive either 4 g CLA/d (2.5 g c9,t11 CLA/d and 0.6 g trans-10, cis-12 CLA/d) or placebo supplements for 6 mo. Aortic pulse wave velocity, blood pressure, anthropometric characteristics, and concentrations of fasting lipid, glucose, insulin, and C-reactive protein were measured before and after supplementation.Results: During the intervention, mean (+/- SE) pulse wave velocity did not change in the c9,t11 CLA group (Delta 0.00 +/- 0.07) compared with the placebo group (Delta 0.09 +/- 0.06). There was no effect of c9,t11 CLA supplementation on blood pressure, body composition, insulin resistance, or concentrations of lipid, glucose, and C-reactive protein.Conclusion: This study does not support an antiatherosclerotic effect or an effect on cardiovascular risk factors of c9,t11 CLA. This trial was registered at www.clinicaltrials.gov as NCT00706745. Am J Clin Nutr 2010; 91: 175-83.

    KW - pulse-wave velocity

    KW - modified Baecke questionnaire

    KW - LDL-phenotype-B

    KW - E knockout mice

    KW - fatty-acids

    KW - cardiovascular-disease

    KW - postmenopausal women

    KW - endothelial function

    KW - lipid-peroxidation

    KW - insulin-resistance

    U2 - 10.3945/ajcn.2009.28192

    DO - 10.3945/ajcn.2009.28192

    M3 - Article

    VL - 91

    SP - 175

    EP - 183

    JO - The American Journal of Clinical Nutrition

    JF - The American Journal of Clinical Nutrition

    SN - 0002-9165

    IS - 1

    ER -